3D-PharmXchange is proud to announce its collaboration with Antleron in the Living Factory 4.0 project. Antleron is a Leuven-based R&D company that develops custom bioprocess solutions for cell & gene therapy applications, with a focus on personalized and digital manufacturing. The Living Factory 4.0, supported by the CrossRoads program, aims to revolutionize the development and production of Advanced Therapy Medicinal Products (ATMPs) through cutting-edge digital solutions.

ATMPs hold immense potential for the future of healthcare, yet their production remains costly and complex. The Living Factory 4.0 project addresses this challenge by developing digital process models, so-called “digital twins”, to streamline process development, optimize resource use, and reduce costs. By integrating these digital applications into a Software-as-a-Service (SaaS) model, biopharmaceutical companies will gain access to efficient, cost-effective, and scalable process optimization tools.

As a partner, 3D-PharmXchange will leverage its expertise in regulatory strategy, CMC, and market access to support the development, validation, and commercialization of these digital solutions. Through extensive industry engagement, beta testing, and regulatory alignment, we will ensure that these innovations meet the needs of ATMP developers and manufacturers.

This collaboration reinforces 3D-PharmXchange’s commitment to advancing ATMP development by bridging the gap between innovation and market readiness. The Living Factory 4.0 project will run from January 2025 to December 2026, paving the way for a more efficient and sustainable ATMP manufacturing landscape.

For more information, visit 3d-pxc.com or www.antleron.com.